[弥漫性大B细胞淋巴瘤的治疗]
[Treatment of diffuse large B-cell lymphoma].
作者信息
Gleissner B, Zwick C, Pfreundschuh M
机构信息
Klinik für Innere Medizin I, Universitätsklinikum Saarland, Homburg.
出版信息
Dtsch Med Wochenschr. 2008 Sep;133(36):1785-94; quiz 1795-6. doi: 10.1055/s-0028-1082813. Epub 2008 Sep 2.
Diffuse large B-cell lymphoma represent 40% of all lymphoma. The development of dose-dense chemotherapeutic regimens and the application of the monoclonal CD20 antibody rituximab improve the prognosis significantly. Evaluation of clinical risk factors (age, stage, LDH, ECOG performance status, number of extranodal involvement) at initial diagnosis are the most important approaches for risk stratification that allows risk adapted modifications of the standard R-CHOP regimen.
弥漫性大B细胞淋巴瘤占所有淋巴瘤的40%。剂量密集化疗方案的发展以及单克隆CD20抗体利妥昔单抗的应用显著改善了预后。在初始诊断时评估临床风险因素（年龄、分期、乳酸脱氢酶、东部肿瘤协作组体能状态、结外受累数量）是进行风险分层的最重要方法，风险分层可使标准R-CHOP方案进行风险适应性调整。
Zotero 插件